P2, N=200, Not yet recruiting, Onyx Axiom

P=N/A, N=60, Completed, The Affiliated Panyu Central Hospital, Guangzhou Medical University; The Affiliated Panyu Central Hospital, Guangzhou Medical University

Strikingly, GGTi-2418@LNP or ketoconazole@LNP combined with T-DXd induced robust and durable tumor regression in HER2-IHC 0 TNBC xenograft models in female mice. Together, this study highlights that targeted inhibition of FBXL2 combined with T-DXd may be a viable therapeutic strategy for treating HER2-IHC 0 solid tumors.

UCS candidemia in children most commonly occurred in patients with solid-hematologic malignancy, central venous catheters and recent antibiotic exposure within 1 week. Female sex, prolonged pre-infection hospitalization, intensive care-related interventions, thrombocytopenia, lower CVC removal rate and elevated C-reactive protein were associated with increased short-term mortality.

Purpose: This study aims to evaluate the effects of itraconazole as a supplementary treatment with paclitaxel and carboplatin on malignancy response and in preventing the initial development of chemoresistance in chemotherapy-naïve patients with advanced ovarian epithelial cancer. Itraconazole was safe and its use was associated with a significant improvement in the quality of life (QOL). Itraconazole could represent a promising add-on therapy to enhance tumor response to chemotherapy in patients with ovarian cancer.

Coadministration of multiple doses of itraconazole, a strong CYP3A4 inhibitor, increased vepdegestrant exposure by 69%, suggesting the involvement of CYP3A4-mediated metabolism, albeit not predominantly, in vepdegestrant elimination.

P1, N=110, Completed, AbbVie | Active, not recruiting --> Completed

P3, N=85, Terminated, Pulmocide Ltd | N=123 --> 85 | Trial completion date: Apr 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Dec 2025; Sponsor Decision

P1/2, N=86, Not yet recruiting, Combined Military Hospital Abbottabad

Management included high-dose acid suppression, short courses of fluconazole for Candida esophagitis, and empiric zinc and riboflavin supplementation; the endoscopic extent of keratinization reduced but persisted, and dysphagia fluctuated without a fixed stricture. Given ongoing symptoms and easy passage of the scope, esophageal manometry was arranged to evaluate a motility contribution, and surveillance endoscopy was planned. This case emphasizes the importance of repeat histology before committing to oncologic pathways, consideration of micronutrient supplementation, cautious use of long-term proton-pump inhibition in patients at risk for Candida, and individualized surveillance where formal guidance is lacking.

This drug-induced partial immunosuppression protocol effectively creates a reproducible state of transient immunodeficiency in outbred mice, suitable for various human tumor xenograft models. It represents a cost-effective and flexible alternative to genetic models, with the distinct advantage of preserving a residual immune microenvironment, making it particularly valuable for preclinical studies that require a partially intact host immune system.

P1, N=110, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting